Financial news in brief: Avecho CBD trial latest; Argent’s milestone delivery; Neurotech reassures ASX by Steve Jones April 29, 2026April 29, 2026 Avecho Biotechnology dosed 244 patients in its phase III insomnia trial, 16% above target, in a […]
